Trial Profile
A Phase 1, Single Dose, Randomized, Cross-over Absolute Bioavailability Study in Healthy Subjects Comparing Oral to Intravenous Administration of GDC-0973.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Cobimetinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 11 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.